Lupin Limited announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin's global research and development efforts across branded, generics and specialty products. With nearly 30 years' experience in drug development in leading global pharmaceutical companies, Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.

Prior to that Dr. Fesharaki held various leadership positions in Teva, Allergan/Actavis, Watson Pharmaceuticals and Apotex. Dr. Fesharaki has extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.